In a number of studies TIMP-3 has been administered as a therapeutic agent and has shown promise to reduce oxygen-induced retinopathy (Hewing et al., 2013) and reduce inflammatory changes in diabetic retinopathy (Abu El-Asrar et al., 2021). Here, TIMP3 is linked to retinal disorder.